Enzo Biochem: Rebecca Fischer
Enzo Biochem has appointed Rebecca Fischer to its board of directors, effective immediately. Her appointment as an independent director follows a process as part of the company's focus on board compositions, refreshment, and diversity. Fisher's appointment, Enzo said, will be a valuable contribution to its women's health business. She replaces Gregory Bortz who retired from the board. Dov Perlysky, who has been on the board since 2012, will replace Bortz as lead independent director of Enzo.
Fisher has been appointed to Enzo's audit, compensation, and nominating/governance committees and will be chair of the audit committee. She is currently CFO of Bellevue Hospital. She began her career there in 2003 and was promoted to deputy CFO in 2016 before becoming CFO in 2017.
SGI-DNA: Brian Donnelly
Synthetic biology firm SGI-DNA announced the appointment of Brian Donnelly to the newly created position of chief commercial officer. Donnelly will be responsible for global sales, marketing, customer service and support, and business development.
Donnelly comes to the firm from Illumina, where he most recently led Illumina's global service organization. During his time at Illumina, Brian also led the global commercial strategy and global clinical marketing teams. He has also held commercial and operational roles at Sequenom, GlaxoSmithKline, and Allergan. He holds MBA and JD degrees from Rutgers University.
Invicro/Konica Minolta Precision Medicine: Matthew Silva and Jack Hoppin
Invicro, a Konica Minolta Company focused on imaging for translational drug discovery and development, has appointed Matthew Silva as CEO. Silva, who will also join Invicro's board, joined the company in 2012 and was most recently executive vice president of scientific applications. He has also worked in leadership positions at Vertex, Amgen, Millenium, and Takeda Pharmaceuticals.
Silva will replace Jack Hoppin as Invicro's CEO. Hoppin is a cofounder of the company and will move from his role as Invicro CEO to be the president of Konica Minolta Precision Medicine. Hoppin will also serve on the boards of both companies.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.